Krishna Yeshwant is Director & 10% Owner at Verve Therapeutics, Inc. (VERV). They have made 9 open-market trades across 2 companies since 2014, most recently 2025-07-25.
CIK 0001585001
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $18.0M since 2023, against 8 sales. Too few scored purchases to measure a record yet.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 80% | 80% |
| Avg Move | -10.2% | -9.1% | -7.3% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| VERV | BUY | 2023-12-01 | 2023-12-05 | $10.00 | $18.0M | +13.8% | +11.7% | +30.0% |
| VERV | SELL | 2022-11-04 | 2022-11-08 | $31.13 | $3.0M | +12.9% | +6.6% | +8.8% |
| VERV | SELL | 2022-11-02 | 2022-11-04 | $33.90 | $5.0M | +1.4% | -12.4% | -1.8% |
| VERV | SELL | 2022-10-31 | 2022-11-02 | $37.95 | $6.5M | -21.5% | -28.5% | -32.3% |
| FMI | SELL | 2017-08-08 | 2017-08-10 | $40.01 | $192K | +0.3% | +6.7% | +38.0% |
| FMI | SELL | 2017-08-04 | 2017-08-08 | $36.85 | $1.3M | -7.6% | +5.7% | +37.4% |
| FMI | SELL | 2015-06-11 | 2015-06-15 | $32.98 | $6.1M | -21.9% | -5.6% | -5.6% |
| FMI | SELL | 2015-05-14 | 2015-05-18 | $38.57 | $332K | -21.9% | -5.6% | -5.6% |
| FMI | SELL | 2014-06-13 | 2014-06-17 | $22.40 | $29.1M | -21.9% | -5.6% | -5.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.